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Background: Aim of this study was to investigate the association of the time under immunosuppression and dif-
ferent immunosuppressive medication on periodontal parameters and selected periodontal pathogenic bacteria of 
immunosuppressed patients after solid organ transplantation (SOT).
Material and Methods: 169 Patients after SOT (lung, liver or kidney) were included and divided into subgroups 
according their time under (0-1, 1-3, 3-6, 6-10 and >10 years) and form of immunosuppression (Tacrolimus, Cy-
closporine, Mycophenolate, Glucocorticoids, Sirolimus and monotherapy vs. combination). Periodontal probing 
depth (PPD) and clinical attachment loss (CAL) were assessed. Periodontal disease severity was classified as 
healthy/mild, moderate or severe periodontitis. Subgingival biofilm samples were investigated for eleven selected 
potentially periodontal pathogenic bacteria using polymerasechainreaction. 
Results: The mean PPD and CAL as well as prevalence of Treponema denticola and Capnocytophaga species was 
shown to be different but heterogeneous depending on time under immunosuppression (p<0.05). Furthermore, 
only the medication with Cyclosporine was found to show worse periodontal condition compared to patients with-
out Cyclosporine (p<0.05). Prevalence of Porphyromonas gingivalis, Tannerella forsythia and Fusobacterium nu-
cleatum was reduced and prevalence of Parvimonas micra and Capnocytophaga species was increased in patients 
under immunosuppression with Glucocorticoids, Mycophenolate as well as combination therapy.
Conclusions: Time under and form of immunosuppression might have an impact on the clinical periodontal and 
microbiological parameters of patients after SOT. Patients under Cyclosporine medication should receive in-
creased attention. Differences in subgingival biofilm, but not in clinical parameters were found for Glucocorti-
coids, Mycophenolate and combination therapy, making the clinical relevance of this finding unclear.
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Introduction
Periodontitis (P) is an inflammatory disease with a mul-
tifactorial character (1). Although P is primarily caused 
by an opportunistic infection with potentially periodon-
tal pathogenic bacteria, host response, general diseases 
(e.g. diabetes mellitus, rheumatoid arthritis, medica-
tion) and environmental factors are involved in the ae-
tiopathogenesis of periodontal inflammation (1).
Considering the role of host response in this context, 
factors influencing the immune reaction of the host 
might be of relevance. Therefore, an immunosuppres-
sive therapy could have an impact on periodontitis se-
verity and progression via alterations in periodontal tis-
sues, gingival overgrowth or ulceration and migration 
of junctional epithelium (2-5). 
One special group receiving life-long immunosup-
pressive therapy consists of patients after solid organ 
transplantation (SOT). Recent studies showed high 
prevalence of periodontal diseases in this patient group 
(liver, lung, kidney), but did not investigate the immu-
nosuppression separately (6-8). Consequently, up until 
now the clinical influence on periodontal parameters 
caused by immunosuppressive medication appears to be 
unclear. Especially the duration of immunosuppressive 
therapy, but also the specific drug as monotherapy or 
combination could be of relevance in this respect. 
In development and progression of P, potentially peri-
odontal pathogenic bacteria play an important role. It 
has been shown, that an ecological shift in the subgingi-
val microbiota is a key component (9,10) Although their 
epidemiological relevance is discussed controversially, 
periodontal pathogenic bacteria as classified by Socran-
sky et al. 1998 (11) are an important element of cur-
rent understanding of pathogenesis of P. The influence 
of immunosuppression on periodontal bacteria is still 
unclear. Few available data for immunosuppressed pa-
tients after organ transplantation showed microbiologi-
cal changes indeed (12-14). However, on the other hand 
differences between immunosuppressed transplant re-
cipients and not immunosuppressed patients were not 
found in recent investigations (6,15). Similarly to peri-
odontal condition, the influence of duration of immu-
nosuppressive therapy and the specific drug as mono-
therapy or combination is unclear. 
Therefore, the aim of this multicenter observational 
cross-sectional study was to investigate the association 
of the duration of immunosuppression and different im-
munosuppressive medication with periodontal parame-
ters and selected periodontal pathogenic bacteria of im-
munosuppressed patients after SOT. For this, patients 
after transplantation of three different organs (kidney, 
liver, and lung) from previous studies by this working 
group should be investigated as one large cohort (6-
8,15). It was hypothesized that the duration and form of 
immunosuppressive therapy would be associated with 
periodontal disease parameters, but not with prevalence 
of selected periodontal pathogenic bacteria. 
Material and Methods
This clinical, observational cross-sectional study was 
reviewed and approved by the ethics committee of the 
University Medical Center Göttingen, Germany (No. 
43/9/07) and by the ethics committee of the University 
Hospital Essen (13-5689-BO). Research was conducted 
in full accordance with the World Medical Associa-
tion’s Declaration of Helsinki. The patients were in-
formed verbally, as well as in writing, about the study 
and provided written informed consent to participate.
- Patients 
For this study, a group consisting of patients after solid 
organ transplantation from previous studies (6-8,15), 
has been composed. For this, previously defined, spe-
cific in- and exclusion criteria were used to select fitting 
patients for this study. Patients after liver and kidney 
transplantation in the Department of General, Visceral 
and Pediatric Surgery of the University Medical Center 
Göttingen (recruited between February to July 2012), 
and patients after lung transplantation from the lung 
transplant unit of the Ruhrlandklinik, Essen, Germany 
(recruited between February and October 2014) were 
investigated during their routine follow up visit.
SOT (kidney, liver, lung), irrespective of time under im-
munosuppression and regular subsequent appointment 
in one of the two transplant centers was the inclusion 
criterion for this study. The following exclusion criteria 
were formulated: age <18 years, presence of any addi-
tional infectious diseases, especially HIV, seizure and 
nervous disorder, as well as pregnancy. Furthermore, 
the inability to undergo complete oral investigation and 
toothlessness leaded to exclusion from the study.
- Recording of general medical conditions
Each patient was asked to complete a questionnaire to 
record the general medical conditions. Thereby, immu-
nosuppressive and further medication, diabetes status, 
smoking habits (smoker = currently smoking, former 
smoker = currently non-smoking but smoked within the 
past 5 years and non-smoker = never smoking or non-
smoking for at least 5 years), causal underlying disease 
for transplantation and time under immunosuppression 
were evaluated. Regarding time under immunosuppres-
sion patients were divided into five groups (0-1 year, 1-3 
years, 3-6 years, 6-10 years and >10 years) for analy-
sis. For the analysis of influence of different immuno-
suppressive medication, only the immunosuppressive 
drugs, which were taken by at least 15 patients, were 
included for analysis. 
- Periodontal examination
All of the patients were examined under standardized 
conditions by an experienced dentist at the dental clinic 
of the University Medical Center Göttingen (kidney and 
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liver), or in in the lung transplant unit of the Ruhrland-
klinik, Essen, Germany (lung), respectively. One hour 
prior to examination, all patients received a single shot 
antibiotic prophylaxis (amoxicillin 2 g or clindamycin 
600 mg at the discretion of the treating physician).
Firstly, a visual inspection of the oral mucosa and the 
gingiva to detect overgrowth was executed. Further-
more, the papillary bleeding index (PBI) has been per-
formed to assess gingival inflammation (16). The bleed-
ing of the marginal gingiva, which was evaluated using 
a periodontal probe (PCP 15; Hu-Friedy, Chicago, IL, 
USA), was the basis for the graduation of PBI score be-
tween 0 (no bleeding/inflammation-free gingiva) and 
4 (profuse bleeding/severe inflammation). For the as-
sessment of the periodontal status, periodontal prob-
ing depth (PPD) and clinical attachment loss (CAL) 
were measured on six measurement points per tooth 
using a millimeter-scaled periodontal probe (PCP 15; 
Hu-Friedy, Chicago, IL, USA). According to the AAP/
CDC, periodontitis was classified into three categories: 
1) severe periodontitis; 2) moderate periodontitis; or 3) 
no/mild periodontitis (17). 
- Microbiological analysis 
Microbiological analysis was performed using subgin-
gival biofilm samples from at least two up to a maxi-
mum of four of the deepest periodontal pockets. After 
placement of cotton rolls to avoid saliva contamination, 
supragingival biofilm was removed from the surface 
of the teeth investigated. After this, sterile paper tips 
were placed in the periodontal pockets for 20 seconds 
and all tips from the same patient were pooled together 
for analysis. Paper tips, which were contaminated with 
blood, were discarded. The microbiological analysis 
of selected potentially periodontal pathogenic bacteria 
was conducted using polymerase chain reaction (PCR). 
The following eleven selected potentially periodontal 
pathogenic bacteria were investigated: Aggregatibacter 
actinomycetemcomitans (Aa, detection threshold >102), 
Porphyromonas gingivalis (Pg), Tannerella forsythia 
(Tf ), Treponema denticola (Td), Prevotella intermedia 
(Pi), Parvimonas micra (PM), Fusobacterium nuclea-
tum (Fn), Campylobacter rectus (Cr), Eubacterium no-
datum (En), Eikenalla corrodens (Ec), Capnocytophaga 
species (Cs); detection threshold >103). All samples were 
analyzed in the clinical laboratory of the Department 
of Preventive Dentistry, Periodontology and Cariology, 
University Medical Center Goettingen, Germany. The 
semiquantitative detection of the bacterial colonization 
of the patients’ oral samples was executed using a com-
mercial test system (Micro-IDentplus®-Test, HainLife-
science, Nehren, Germany) according to the manufac-
turers protocol. In brief, amplification was performed 
with a 35-µl mixture of primers and dNTPs (Hain Life-
science, Nehren, Germany), 10.5 µl Mastermix (Qia-
gen, Hilden, Germany) and 5 µl of the DNA sample or 
5 µl of water as a negative control, respectively. The 
amplification cycles were executed in a thermo cycler 
(Biometra, Goettingen, Germany). The hybri-dization 
was performed following the Micro-IDent plus proto-
col in a TwinCubator (Hain Lifescience, Nehren, Ger-
many). Only the prevalence of the selected bacteria was 
considered for analysis.   
- Statistical analysis 
Statistical analysis was performed using SPSS, version 
24.0 (SPSS Inc., US). Kolmogorow-Smirnow-test was 
used to test the metric variables for their normal dis-
tribution. Thereby, none of the tested variables showed 
normal distribution. Accordingly, only non-parametric 
tests for non-normal distributed samples were per-
formed. A comparison of more than 2 independent, 
non-normal distributed samples was executed using 
Kruskal-Wallis test, while categorical data were ana-
lyzed using Chi² or Fisher test, respectively. The signifi-
cance level was set at p<0.05.
Results
- Patients
A total of 169 immunosuppressed patients after organ 
transplantation with a mean age of 55.44 ± 11.10 years 
and an average time of 7.00 ± 5.72 years under immu-
nosuppression could be included. The immunosuppres-
sive medication, which were included for analysis were 
Tacrolimus, Cyclosporine, Mycophenolate, Glucocorti-
coids and Sirolimus, whereby 77% of patients received 
a combination of at least two different medications 
(Table 1). 
- Periodontal examination
Five percent of patients showed a gingival overgrowth, 
of which significantly more patients received medica-
tion with cyclosporine (63% vs. 37%; p<0.01). Accord-
ing to the classification of the AAP/CDC, 17% of pa-
tients showed no or mild periodontitis, while 56% were 
found to present a moderate, and 27% a severe peri-
odontitis. Thereby, the number of remaining teeth was 
on average 17.77 ± 7.56. The periodontal findings are 
given in table 2.
- Periodontal parameters depending on time under and 
form of immunosuppression
The mean PPD and mean CAL was shown to be differ-
ent but heterogeneous depending on time under immu-
nosuppression (p<0.05, table 3). In analysis of selected 
immunosuppressive drugs, cyclosporine was found 
to present higher mean PPD (p=0.04), mean and max 
CAL (p=0.05) as well as periodontal disease severity 
(p=0.02, table 4). 
- Periodontal bacteria depending on time under and 
form of immunosuppression
Out of the selected potentially periodontal pathogenic 
bacteria, for Td and Csp heterogeneous, but statistically 
significant differences in the prevalence depending on 
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total (n=169)
























Table 1. Characteristics of patients.
total (n=169)
remaining teeth [mean ± SD] 17.77 ± 7.56
PBI [mean ± SD] 0.40 ± 0.57
PPD [mean ± SD]
max 4.70 ± 1.37
mean 3.34 ± 0.61
CAL [mean ± SD]
max 5.82 ± 2.21






gingival overgrowth [% (n)] 5%(8)
Table 2. Periodontal findings of patients.
[PBI: papilla bleeding index, PPD: periodontal probing depth, CAL: 
clinical attachement loss, SD: standard deviation]
time under immunosuppression in years
p-value
0-1 1-3 3-6 6-10 <10
PPD
[mean ± SD] 
max 4.62 ± 0.92 4.95 ± 1.69 4.94 ± 1.30 4.51 ± 1.05 4.44 ± 1.54 0.26
mean 3.44 ± 0.55 3.23 ± 0.51 3.62 ± 0.66 3.28 ± 0.62 3.18 ± 0.60 <0.01
CAL 
[mean ± SD]
max 5.43 ± 1.36 6.08 ± 2.69 6.59 ± 2.41 5.56 ± 1.92 5.31 ± 2.01 0.16




healthy/mild 10%(2) 23%(9) 12%(4) 15%(6) 22%(8)
0.10moderate 76%(16) 51%(20) 41%(14) 62%(24) 58%(21)
severe 14%(3) 26%(10) 47%(16) 19%(7) 19%(7)
Table 3. Periodontal findings depending on time under immunosuppression.
[PPD: periodontal probing depth, CAL: clinical attachement loss, SD: standard deviation; significance level p<0.05].
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time under immunosuppression were found (p<0.05, 
figure 1).
Patients under immunosuppression with Glucocorticoids 
showed significantly lower prevalence of Pg (p=0.03), 
Tf (p=0.04) and Fn (p=0.01) and higher pre-valence 
of Pm (p<0.01) and Csp (p<0.01) compared to patients 
without glucocorticoid medication. Also for combination 
vs. monotherapy, lower prevalence of Pg (p<0.01), Tf 
(p=0.01) and a trend for Fn (p=0.07) as well as a higher 
prevalence of Pm (p=0.03) and a trend for Csp (p=0.07) 
were found.  Similar results were found for Mycopheno-
late with lower prevalence of Pg (p<0.01), Tf (p<0.01) 
and Fn (p=0.01) as well as a trend for higher prevalence 
of Pm (p=0.06). Furthermore, patients with Tacrolimus 
showed a lower prevalence of Pg compared to patients 
without Tacrolimus (p=0.01, figure 2).
Fig. 1. Prevalence of selected periodontal pathogenic bacteria depending on time under immunosuppression.
Fig. 2. Distribution of selected periodontal pathogenic bacteria depending on immunosuppressive medication.
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Discussion
- Main results: Time under immunosuppression was 
associated with both, the clinical periodontal findings 
(PPD and CAL) and prevalence of selected potentially 
periodontal pathogenic bacteria (p<0.05). However, 
these results were heterogeneous between the selected 
groups (0-1 year, 1-3 years, 3-6 years, 6-10 years and 
>10 years). Patients under medication with Cyclospo-
rine were found to show worse periodontal conditions 
compared to patients without Cyclosporine, but further 
association of immunosuppressive medication with 
clinical parameters was not found. In contrast, medica-
tion with Mycophenolate, Glucocorticoids and combi-
nation of different immunosuppressive drugs was found 
to show lower prevalence of Pg, Tf and Fn, while the 
prevalence of Pm and Csp was reduced. 
- Interpretation: To the best of authors’ knowledge, 
studies about the influence of different immunosup-
pressive medications are rare and partly outdated, what 
limits the comparability with the current study. The ef-
fect of immunosuppressive medication on periodontal 
condition has already been evaluated in existing review 
articles (2,18) The time under immunosuppression was 
shown to influence the periodontal parameters and 
subgingival plaque composition; however the evalua-
tion was just between 90 days and 9 months (14,19,20) 
and in very small patient cohorts, including exclusively 
patients after kidney transplantation. No long-term re-
sults are available in the recent literature. As the current 
study is limited by the character of a cross-sectional 
study, the influence of immunosuppression in follow-
up could not be assessed and therefore this can only be 
assumed based on the current study’s findings. An as-
sociation with periodontal parameters and several bac-
teria was found indeed, but a clear tendency over the 
time e.g. a higher progression of periodontal destruction 
with increasing time under immunosuppression cannot 
be derived. Further study ś with a longitudinal design 
would be necessary to clarify the influence of time since 
immunosuppression on clinical and microbiological pa-
rameters. 
The more promising approach is the difference of inves-
tigated parameters between different immunosuppres-
sive drugs. Some, but partly outdated data are available 
regarding this issue. It has been shown, that immuno-
suppressive medication might reduce periodontal in-
flammation in patients after kidney transplantation (21). 
These results were discussed controversially, but a re-
duced periodontal inflammation in immunosuppressed 
compared to non-immunosuppressed patients appears 
probable (2,18). The current study did not investigate 
periodontal inflammation in particular, but the missing 
differences in all periodontal parameters of the medica-
tion groups except for Cyclosporine makes the clinical 
relevance and validity of the available studies unclear. 
An aspect of potential clinical relevance could be the 
worse clinical periodontal parameters between pa-
tients with and without Cyclosporine. Cyclosporine is 
well known to be associated with gingival overgrowth 
(2,21), what is in line with the current study’s findings, 
even though only eight patients showed gingival over-
growth. However, the influence on periodontal destruc-
tion is discussed controversially based on animal studies 
(22,23). The gingival overgrowth might explain higher 
PPD in patients with Cyclosporine. However, in the cur-
rent study only very few patients were found to present 
gingival overgrowth. Therefore, based on the clinical 
findings of the current study, an influence of Cyclospo-
rine on periodontal destruction appears probable, what is 
contradictory to the recent investigations (22,23).
As a further finding, differences in the prevalence of sev-
eral potentially periodontal pathogenic bacteria (Pg, Tf, 
Fn, Pm, Csp) were found in patients receiving Glucocor-
ticoids, Mycophenolate as well as the combination of at 
least two immunosuppressive drugs. Thereby, a kind of 
shift can be observed, in which classical periodontitis as-
sociated pathogens as Pg, Tf and Fn are reduced in their 
prevalence, while the prevalence of other bacteria as Pm 
and Csp is increased. Only little literature is available, 
which exclusively investigated immunosuppressed pa-
tients after kidney transplantation (12-14). Thereby, the 
results of Vieira et al. show a lower prevalence of pu-
tative anaerobic bacteria in immunosuppressed kidney 
transplant recipients (13). This is in line with the current 
study’s findings. The subgingival biofilm is complex and 
associated with several environmental factors as well as 
the host response (24,25). As the “classical” periodontal 
pathogenic bacteria including Pg and Tf have the poten-
tial to penetrate gingival epithelium and influence the 
host response, it is discussed whether these bacteria need 
inflammatory mediators in the gingival crevicular fluid 
for nutrition (26,27). If it is considered that inflammation 
might be reduced under immunosuppressive medication, 
the environmental conditions in periodontal pocket could 
be less favorable for these bacteria in case of immuno-
suppression. Furthermore, Fn is important in the forma-
tion of periodontal pathogenic biofilm as it can bind a lot 
of other bacteria (28), and reduce oxygen levels, what 
improves the ecological conditions for anaerobe bacteria 
like Pg (29). Consequently, reduction of Fn due to im-
munosuppression resulting in reduction of Pg could be a 
further approach. 
The combination of different immunosuppressive medi-
cation, but also the usage of Glucocorticoids and My-
cophenolate could mean a strong immunosuppression, 
resulting in higher changes in subgingival biofilm. Nev-
ertheless, this appears to have no influence on the peri-
odontal burden of the patients in the current study, as 
it is similar between different medications. Therefore, 
clinical relevance of this finding is questionable. 
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- Strengths and limitations: This is the first study inves-
tigating the association of the duration of immunosup-
pression and different immunosuppressive medication 
with periodontal parameters and selected periodontal 
pathogenic bacteria of immunosuppressed patients after 
SOT. The large cohort and the comprehensive investiga-
tion is the major strength of the study. However, it is 
limited by the design as a cross-sectional study, which 
is not possible to provide strong findings on the longi-
tudinal development. Furthermore, the patient group is 
heterogeneous as it includes different organs with dif-
ferent causal underlying diseases. However, patients 
after SOT are a difficult patient group and a high case 
number is hard to achieve within one singular organ. 
The missing assessment of periodontal inflammation 
(BOP) is a major limitation of the study, as it is only 
possible to illustrate the periodontal disease burden of 
the patients based on PPD and CAL. Furthermore, the 
investigation of only 11 selected potentially periodontal 
pathogenic bacteria is not able to illustrate the complex 
biofilm and must always take the clinical results into ac-
count (30). Accordingly, the separation of the subgroups 
according to their periodontal disease severity would 
provide stronger findings, but was omitted because of 
the low case number that the subgroups would have.
Besides these limitations, the study provides clinical 
findings of a large cohort of immunosuppressed patients 
and provides new findings regarding clinical and micro-
biological parameters of this patients group. 
Conclusions
Within the limitations of the study it has been shown that 
time under and form of immunosuppression is associ-
ated with clinical periodontal and microbiological pa-
rameters of patients under SOT. Thereby, Cyclosporine 
medication could be associated with worse periodontal 
condition, making a more intensive dental care of these 
patients necessary. Furthermore, a shift in subgingival 
biofilm in case of medication with Glucocorticoids and 
Mycophenolate as well as combination of immunosup-
pressive medication can be assumed. The clinical conse-
quence and thus relevance of this finding appears unclear. 
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